Subject(s)
COVID-19 , Drug Hypersensitivity , Skin Diseases , Antiviral Agents , Drug Hypersensitivity/diagnosis , Humans , SARS-CoV-2Subject(s)
COVID-19/pathology , Erythema Multiforme/pathology , Adrenal Cortex Hormones/therapeutic use , Aged , Anti-Bacterial Agents/therapeutic use , Antiviral Agents/therapeutic use , Azithromycin/therapeutic use , C-Reactive Protein/metabolism , COVID-19/blood , COVID-19/physiopathology , Ceftriaxone/therapeutic use , Drug Combinations , Erythema Multiforme/blood , Erythema Multiforme/drug therapy , Female , Fibrin Fibrinogen Degradation Products/metabolism , Hospitalization , Humans , Hydroxychloroquine/therapeutic use , Lopinavir/therapeutic use , Lymphocyte Count , Middle Aged , Ritonavir/therapeutic use , COVID-19 Drug TreatmentABSTRACT
COVID-19 is an infectious disease caused by severe acute respiratory coronavirus 2 (SARS-CoV-2). Vesicular skin rashes have been reported as associated with COVID-19, but there is little information about this cutaneous manifestation. We designed a prospective observational study of patients diagnosed with COVID-19 who had vesicular lesions. Clinical characterization of skin findings was conducted by dermatologists. When possible, histological analysis and detection of SARS-CoV-2 in the content of the vesicles was performed. In total, 24 patients were included. A disseminated pattern was found in 18 patients (75%), and a localized pattern was found in 6 (25%). Median duration of the skin rash was 10 days. Of the 24 patients, 19 (79.2%) developed the skin rash after the onset of COVID-19 symptoms. Histological examination in two patients was consistent with viral infection, SARS-CoV-2 was not detected in four patients. This single-centre study shows the clinical characteristics of vesicular skin rashes in patients with COVID-19.
Subject(s)
Blister/virology , COVID-19/complications , Exanthema/virology , Adult , Aged , Blister/pathology , Exanthema/pathology , Female , Humans , Male , Middle Aged , Prospective Studies , SARS-CoV-2/isolation & purification , Young AdultSubject(s)
Antiviral Agents/therapeutic use , Coronavirus Infections/diagnosis , Pneumonia, Viral/diagnosis , Severe Acute Respiratory Syndrome/diagnosis , Vasculitis, Leukocytoclastic, Cutaneous/etiology , Aged , Biopsy, Needle/methods , COVID-19 , COVID-19 Testing , Clinical Laboratory Techniques , Coronavirus Infections/drug therapy , Coronavirus Infections/pathology , Diagnosis, Differential , Drug Therapy, Combination , Emergency Service, Hospital , Female , Humans , Immunohistochemistry , Pandemics , Pneumonia, Viral/drug therapy , Pneumonia, Viral/pathology , Radiography, Thoracic/methods , Severe Acute Respiratory Syndrome/drug therapy , Severe Acute Respiratory Syndrome/pathology , Treatment Outcome , Vasculitis, Leukocytoclastic, Cutaneous/pathology , COVID-19 Drug TreatmentSubject(s)
Head and Neck Neoplasms/pathology , Neoplasms, Basal Cell/pathology , Scalp/pathology , Skin Neoplasms/pathology , Biopsy , Diagnosis, Differential , Hair Follicle/pathology , Head and Neck Neoplasms/surgery , Humans , Lymphatic Metastasis/diagnosis , Male , Middle Aged , Neoplasms, Basal Cell/surgery , Pseudolymphoma/diagnosis , Scalp/surgery , Skin Neoplasms/surgeryABSTRACT
The vast majority of patients treated with radiotherapy develop dermatological side effects. Acute radiation dermatitis or chronic skin fibrosis are well known sequels of radiation, but there are also other infrequent skin toxicities following external radiotherapy we should be aware of. We present a case of a rare form of delayed radiation dermatitis consisting of a localized acneiform eruption, confirmed by skin biopsy, in the irradiated fields in a woman with breast cancer. We review the clinical characteristics and risk factors available in the literature about this unusual adverse effect of radiotherapy. It is important for dermatologists to recognize this rare adverse effect, owing to the important impact on physical and psychosocial health of the patients and because it may delay the surgical reconstruction.